Cartilage intermediate layer protein 2 (CILP2) facilitates interactions between matrix components in cartilage and has emerged as a potential prognostic biomarker for cancer. This study aimed to investigate the function and mechanisms ofCILP2in pan-cancer. We evaluated the pan-cancer expression, methylation, and mutation data ofCILP2for its clinical prognostic value. Additionally, we explored the immunological characteristics ofCILP2in pan-cancer and then focused specifically on pancreatic ductal adenocarcinoma (PAAD). The subtype analysis of PAAD identified subtype-specific expression and immunological characteristics. Finally, in vitro and in vivo experiments assessed the impact ofCILP2on pancreatic cancer progression.CILP2exhibited high expression in most malignancies, with significant heterogeneity in epigenetic modifications across multiple cancer types. The abnormal methylation and copy number variations inCILP2were correlated with poor prognoses. UpregulatedCILP2was associated withTGFB/TGFBR1and more malignant subtypes.CILP2exhibited a negative correlation with immune checkpoints in PAAD, suggesting potential for immunotherapy.CILP2activated the AKT pathway, and it increased proliferation, invasion, migration, and epithelial–mesenchymal transition (EMT) in pancreatic cancer. We demonstrated thatCILP2significantly contributes to pancreatic cancer progression. It serves as a prognostic biomarker and a potential target for immunotherapy.
软骨中间层蛋白2（CILP2）在软骨中促进基质成分间的相互作用，并已成为癌症的潜在预后生物标志物。本研究旨在探讨CILP2在泛癌中的功能与机制。我们评估了CILP2在泛癌中的表达、甲基化及突变数据，以分析其临床预后价值。此外，我们探索了CILP2在泛癌中的免疫学特征，并特别聚焦于胰腺导管腺癌（PAAD）。通过对PAAD的亚型分析，我们识别了亚型特异性表达及免疫学特征。最后，通过体外与体内实验评估了CILP2对胰腺癌进展的影响。结果显示，CILP2在多数恶性肿瘤中高表达，且其表观遗传修饰在多种癌症类型中表现出显著异质性。CILP2的异常甲基化与拷贝数变异与不良预后相关。CILP2的上调与TGFB/TGFBR1通路及更具侵袭性的亚型相关。在PAAD中，CILP2与免疫检查点呈负相关，提示其免疫治疗潜力。CILP2激活了AKT通路，并促进胰腺癌的增殖、侵袭、迁移及上皮-间质转化（EMT）。本研究证实CILP2显著促进胰腺癌进展，可作为预后生物标志物及免疫治疗的潜在靶点。
肿瘤(癌症)患者之家